Novo Nordisk Skyrockets To $506B Valuation Driven By 'Miracle' Drugs Ozempic, Wegovy
Novo Nordisk Skyrockets To $506B Valuation Driven By 'Miracle' Drugs Ozempic, Wegovy
The company predicts a sales growth of 18% to 26% in CER terms for the current year, driven by the soaring demand for Wegovy and Ozempic, which contain the same active ingredient.$Novo-Nordisk A/S (NVO.US)$, the Danish pharmaceutical company, saw its market value soar to $506 billion on Wednesday following the release of its 2023 earnings, driven by a surge in demand for its key drugs in the past quarter.
$諾和諾德 (NVO.US)$這家丹麥製藥公司在公佈2023年業績後，週三其市值飆升至5,060億美元，這得益於上個季度對其關鍵藥物的需求激增。
This increase in value was attributed to the high demand for Novo Nordisk's weight loss drug, Wegovy, and diabetes drug, Ozempic.
價值的增長歸因於對諾和諾德的減肥藥物Wegovy和糖尿病藥物Ozempic的高需求。
Novo Nordisk's 2023 sales rose by 31% in Danish kroner and 36% at constant exchange rates (CER) to 232.3 billion kroner ($33.71 billion). The full-year operating profit also significantly increased, rising by 37% in kroner and 44% at constant exchange rates to 102.6 billion kroner.
諾和諾德2023年的銷售額以丹麥克朗計算增長了31％，按固定匯率（CER）計算增長了36％，達到2323億克朗（合337.1億美元）。全年營業利潤也大幅增長，按克朗計算增長了37％，按固定匯率計算增長了44％，達到1,026億克朗。
The company predicts a sales growth of 18% to 26% in CER terms for the current year, driven by the soaring demand for Wegovy and Ozempic, which contain the same active ingredient.
該公司預測，按恒定匯率計算，本年度的銷售額將增長18％至26％，這要歸因於對含有相同活性成分的Wegovy和Ozempic的需求激增。
Novo Nordisk's 2023 results were largely influenced by the strong performance of its diabetes and obesity care division, with obesity care experiencing a 154% spike at CER to 41.6 billion.
諾和諾德2023年的業績在很大程度上受到其糖尿病和肥胖症護理部門的強勁表現的影響，按CER計算，肥胖症護理增長了154％，達到416億。
The surge in demand for Novo Nordisk's drugs comes amid reports of counterfeit versions of its medications. The rising demand for Ozempic and its sister medication, Wegovy, has led to reports of salons and social media distributors selling knockoff versions.
對Novo Nordisk藥品的需求激增之際，有報道稱其藥物存在假冒版本。對Ozempic及其姊妹藥物Wegovy的需求不斷增加，導致有報道稱沙龍和社交媒體分銷商出售仿冒品。
Despite this, the company's market value has continued to rise, with notable investors taking a bullish stance on Novo Nordisk's options. This suggests that the market is confident in the company's ability to maintain its growth trajectory.
儘管如此，該公司的市值仍在持續上漲，知名投資者對諾和諾德的期權持看漲立場。這表明市場對公司維持增長軌跡的能力充滿信心。
Novo Nordisk's CEO, Lars Fruergaard Jørgensen, acknowledged the emergence of competition in the weight-loss market, particularly from U.S. stalwart Eli Lilly. Jørgensen believes that this competition will ultimately benefit patients and drive further growth in the obesity care market.
諾和諾德首席執行官拉斯·弗魯爾加德·約根森承認減肥市場出現了競爭，特別是來自美國巨頭禮來公司的競爭。約根森認爲，這場競爭最終將使患者受益，並推動肥胖症護理市場的進一步增長。
Despite potential price pressures from this competition, Novo Nordisk remains confident in the continued global demand for its products. The company is investing heavily in expanding its production capacity to meet this demand, with construction already underway on several projects.
儘管這場競爭可能帶來價格壓力，但諾和諾德對全球對其產品的持續需求仍然充滿信心。該公司正在大力投資擴大其生產能力以滿足這一需求，多個項目已經在建設中。